| Date | Title | Description |
| 10.11.2025 | Japan’s €33B bet on Europe: deeptech & AI lead as cross-border investment surges | A new report by NordicNinja, Europe’s largest Japan-backed VC and backers of fast-growing tech companies including Bolt, Starship and Varjo, and Dealroom reveals that €33 billion of Japan-linked capital has flowed into Europe since 2019 as ... |
| 27.05.2025 | Cereno Scientific is nominated and shortlisted for ‘Company of the Year’ in the European Mediscience Awards 2025 | Cereno Scientific is nominated and shortlisted for ‘Company of the Year’ in the European Mediscience Awards 2025
Tue, May 27, 2025 08:15 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneerin... |
| 23.05.2025 | Everest Medicines Announces NEFECON® Inclusion in China's Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review) | SHANGHAI, May 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of in... |
| 15.05.2025 | A New Dawn for COPD Treatment: Dupixent's Approval in Singapore | In a significant breakthrough for chronic obstructive pulmonary disease (COPD) patients, Singapore has approved Dupixent (dupilumab) as the first biologic treatment for this debilitating condition. This decision, announced on May 14, 2025, ... |
| 13.05.2025 | Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S. | Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.
Tue, May 13, 2025 08:00 CET Report this content
Lund, Sweden, 13 May 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Maria ... |
| 07.05.2025 | Everest Medicines Announces NMPA Full Approval of NEFECON® for the Treatment of Primary Immunoglobulin A nephropathy (IgAN) in Adults at Risk of Disease Progression | SHANGHAI, May 7, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of inn... |
| 14.12.2024 | Niwot's Triumph: A Cross Country Championship Journey | In the world of high school sports, few stories shine as brightly as that of the Niwot Cougars. This year, they sprinted to glory, claiming the national championship at the Nike Cross in Oregon. It was a journey marked by grit, determinatio... |
| 09.12.2024 | Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial | Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026
Appoints US-based Chief Commercial Officer, Andrew Udell
Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian ... |
| 04.12.2024 | Sinclair Announces New Executive Leadership to Support Global Growth Trajectory | Sinclair
Sinclair is excited to announce the appointment of three dynamic leaders to its executive leadership team, marking a pivotal transition in propelling Sinclair into its next phase of growth, innovation, and market leadership. Frank ... |
| 28.11.2024 | Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List | SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 23.10.2024 | NEFECON®: A Beacon of Hope for IgA Nephropathy Patients in Asia | In the realm of biopharmaceuticals, few developments shine as brightly as the recent approval of NEFECON® by the Taiwan Food and Drug Administration (TFDA). This groundbreaking treatment, designed for primary immunoglobulin A nephropathy (I... |
| 22.10.2024 | Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in "Kidney 360" Magazine | SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of in... |
| 21.10.2024 | Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy | SHANGHAI , Oct. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of i... |
| 16.09.2024 | Asahi Kasei announces the final outcome of the public cash offer for Calliditas | Asahi Kasei announces the final outcome of the public cash offer for Calliditas
Mon, Sep 16, 2024 15:00 CET Report this content
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER TO SELL ANY SHARES OR AME... |
| 06.09.2024 | Asahi Kasei's Strategic Acquisition: A New Era for Calliditas Therapeutics | In a significant move that reshapes the landscape of biopharmaceuticals, Asahi Kasei Corporation has successfully completed its public cash offer for Calliditas Therapeutics AB. With a commanding 93.30% ownership of Calliditas, Asahi Kasei ... |
| 06.09.2024 | Calliditas Therapeutics: A New Chapter Begins Amidst Corporate Changes | In the world of pharmaceuticals, change is the only constant. Calliditas Therapeutics AB, a biopharmaceutical company based in Stockholm, is poised to undergo significant transformations following a recent announcement from Asahi Kasei Corp... |
| 05.09.2024 | Raising Awareness and Empowering Patients: The Fight Against Kidney Disease | Kidney disease is a silent predator. It lurks in the shadows, often unnoticed until it strikes. The statistics are alarming. Approximately 35.5 million adults in the U.S. have chronic kidney disease (CKD), yet around 90% are unaware of thei... |
| 03.09.2024 | NephCure Announces First-Ever IgA Nephropathy (IgAN) Awareness Day on September 26, 2024 | PHILADELPHIA, Sept. 3, 2024 /PRNewswire/ -- NephCure, a leading nonprofit organization dedicated to finding better treatments and a cure for rare kidney disease, is proud to announce the inaugural IgA Nephropathy (IgAN) Awareness Day on Sep... |
| 03.09.2024 | Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) | Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Tue, Sep 03, 2024 12:00 CET Report this content
The shareholders of Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”), Reg. No. 556659-9766, with registered of... |
| 02.09.2024 | Asahi Kasei completes the recommended public cash offer and becomes the owner of 93.30 per cent of all shares in Calliditas | Asahi Kasei completes the recommended public cash offer and becomes the owner of 93.30 per cent of all shares in Calliditas
Mon, Sep 02, 2024 15:00 CET Report this content
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICI... |
| 14.08.2024 | Calliditas and Asahi Kasei: A Strategic Dance in the Biopharma Arena | In the fast-paced world of biopharmaceuticals, every move counts. Calliditas Therapeutics AB, a Swedish biopharma company, recently unveiled its interim report for the first half of 2024. The numbers tell a story of growth, challenges, and ... |
| 13.08.2024 | Asahi Kasei publishes a supplement to the offer document for the recommended public cash offer for Calliditas | Asahi Kasei publishes a supplement to the offer document for the recommended public cash offer for Calliditas
Tue, Aug 13, 2024 17:30 CET Report this content
THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN O... |
| 31.07.2024 | Calliditas Therapeutics: Navigating Shareholder Waters Amidst Corporate Changes | In the world of finance, numbers tell stories. They pulse with the rhythm of market dynamics, reflecting the health of companies and the sentiments of investors. Calliditas Therapeutics AB, a biopharmaceutical company based in Stockholm, re... |
| 31.07.2024 | Number of shares and votes in Calliditas Therapeutics | Number of shares and votes in Calliditas Therapeutics
Wed, Jul 31, 2024 14:00 CET Report this content
During July, the number of shares and votes in Calliditas Therapeutics AB (publ) has changed due to the exercise of warrants under the com... |
| 26.07.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders | NEW YORK, July 26, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| 04.07.2024 | Launch of Phase 3 clinical trial with Nefecon in Japan | Launch of Phase 3 clinical trial with Nefecon in Japan
Thu, Jul 04, 2024 08:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announces that its partner Viatris Pharmaceutical... |
| 28.05.2024 | Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress | Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Tue, May 28, 2024 14:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced the p... |
| 15.05.2024 | Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm | Calliditas Therapeutics to Present Data at ERA 2024 May 23 – 26 in Stockholm
Wed, May 15, 2024 14:00 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data pr... |
| 15.05.2024 | Notice of annual general meeting of Calliditas Therapeutics AB (publ) | Notice of annual general meeting of Calliditas Therapeutics AB (publ)
Wed, May 15, 2024 12:00 CET Report this content
The shareholders of Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”), Reg. No. 556659-9766, with registered o... |
| 14.05.2024 | Everest Medicines Announces Commercial Launch and First Prescription for NEFECON® in Mainland China | SHANGHAI, May 14, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of inn... |
| 18.04.2024 | Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024 | Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Thu, Apr 18, 2024 13:00 CET Report this content
Calliditas Therapeu... |
| 06.11.2023 | Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023 | Calliditas Presents Additional Data Analyses from the NefIgArd Phase 3 trial at the American Society of Nephrology (ASN) Kidney Week 2023
Mon, Nov 06, 2023 21:30 CET Report this content
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stock... |
| 28.04.2023 | Notice of annual general meeting of Calliditas Therapeutics AB (publ) | Notice of annual general meeting of Calliditas Therapeutics AB (publ)
Fri, Apr 28, 2023 08:30 CET Report this content
The shareholders of Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”), Reg. No. 556659-9766, with registered o... |
| 16.12.2021 | Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy | TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-crea... |
| 16.12.2021 | Milestone for Calliditas as FDA grants accelerated approval of TARPEYO™ | Our portfolio company Calliditas Therapeutics reached a major milstone yesterday with its accelerated FDA approval of Tarpeyo™, a novel therapy indicated for patients with nephropathy. Industrifonden was the first institutional venture inve... |
| 19.07.2021 | Calliditas Therapeutics : secures $75 million term loan facility (Form 6-K) | Calliditas secures $75 million term loan facility
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the company has signed a loan agreement of up to the Euro equivalent of $75 million wit... |
| 15.07.2021 | Calliditas Secures $75 Million Term Loan Facility | Calliditas Therapeutics AB announced that the company has signed a loan agreement of up to the Euro equivalent of $75 million with Kreos Capital. Proceeds from the loan will be utilized for the launch of Calliditas' lead product candidate N... |
| 15.07.2021 | Calliditas secures $75 million term loan facility | Calliditas secures $75 million term loan facility Thu, Jul 15, 2021 08:20 CET
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the company has signed a loan agreement of up to the Euro e... |
| 15.07.2021 | Calliditas Therapeutics : secures $75 million term loan facility | Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed a loan agreement of up to the Euro equivalent of $75 million with Kreos Capital. Proceeds from the loan ... |
| 27.04.2021 | CALLIDITAS THERAPEUTICS AB (PUBL)
Calliditas Therapeutics : Corporate Governance Report 2020 | Corporate Governance Report
Introduction
Calliditas Therapeutics AB (publ), "Calliditas" is a Swedish public limited liability company with its registered office in Stockholm. The company's share was listed on June 29, 2018 on Nas... |
| 29.06.2018 | Trading in Calliditas’ share commences today on Nasdaq Stockholm | Calliditas Therapeutics AB (publ) today announces the outcome of the offering of new shares in the Company and the listing of the Company’s share on Nasdaq Stockholm. The SEK 650 million offering was substantially over-subscribed, attractin... |
| 18.06.2018 | Industrifonden Life Science recruits Bita Sehat as Investment Manager | Industrifonden strengthens its Life Science investment team through the recruitment of Dr. Bita Sehat as Investment Manager. Bita brings over 10 years of scientific expertise in oncology as well as corporate experience from Europe and North... |
